Autor(es)

Souto, Fernanda Maria Silveira ; Missaka, Ruy Felippe Brito Goncalves ; Lavezzo, Marcelo Mendes ; Nobrega, Priscilla Figueiredo Campos ; Sakata, Viviane Mayumi ; Oyamada, Maria Kiyoko ; Hirata, Carlos Eduardo ; Yamamoto, Joyce Hisae

• Tipo de documento: Artigo Científico
• Fonte: OCULAR IMMUNOLOGY AND INFLAMMATION; v. N/A, p. 7-pg., 2023-01-13.

Resumo

AimsTo investigate the changes in quality-of-life (QoL) metrics at a 24-month interval in non-acute VKHD patients and their association with inflammation, treatment, and visual function.MethodsSF-36 and VFQ-25 questionnaires were administered at two 24-month-apart moments to 22 non-acute VKHD patients followed for >= 12 months since acute disease onset. "Improvement," "unchanged," or "worsening" in questionnaires scores (difference >5-point) between M1 and M2 and their associations were sought.ResultsAbsence of systemic treatment or optic disc hyperfluorescence was associated with improved general health (SF-36). Improvement in binocular contrast sensitivity resulted in better ocular pain score; absence of anterior uveitis relapse, stable fundus findings, no use of cyclosporine or no intravitreal injections resulted in unchanged/better dependency score; no intravitreal injections resulted in unchanged/better mental health score (VFQ-25).ConclusionStability/improvement in QoL scores was associated with controlled inflammation, better visual function, and no need for treatment. Subclinical inflammatory signs did not impact QoL scores. (AU)

• Processo FAPESP: 11/50936-7 - Doença de Vogt-Koyanagi-Harada: parâmetros para tratamento efetivo na fase aguda e no estágio tardio
• Beneficiário: Joyce Hisae Yamamoto Takiuti
• Modalidade de apoio: Auxílio à Pesquisa - Regular